Objective. The main objective was to determine the prevalence of anti-dense fine speckled (DFS70) antibodies in a stable population of undifferentiated connective tissue disease (UCTD) to better define their potential role.
Introduction
The clinical phenotype of connective tissue disease (CTD) is widely heterogeneous and can be undifferentiated when the presence of signs and symptoms suggestive of autoimmune disease do not fulfill the classification criteria for a defined CTD [18] .
It has been shown that two-thirds of undifferentiated CTD (UCTD) patients eventually develop a classical CTD and typically within the first 5 years of suspected diagnosis [923] . UCTD may evolve into SLE, SSc, SS, mixed CTD, systemic vasculitis, PM/DM and more rarely, RA [10, 11, 13, 2428] . UCTD patients were historically described as having undifferentiated or lanthanic collagen disease, since they clinically were characterized by an inflammatory tissue injury [29] . Later, in 1980, Le Roy introduced the new term UCTD to better define the early stage of CTD alluding to the concept that the condition could also remain indefinitely as an undifferentiated form of disease [30] . Although the pathogenesis of UCTD is still unknown, nowadays clinical and serological features are defined in the UCTD condition.The most common symptoms are arthralgia (3780%), non-erosive arthritis (1470%), RP (4560%), leukopenia (1142%), xerostomia (740%), xerophtalmia (836%), cutaneous rash and oral aphtosis [31] . The serological profile is positive for ANA (58100%), anti-Ro/SSA (830%), anti-RNP (1030%), anti-dsDNA and aPL [9, 13, 15, 19, 32, 33] . Moreover, 80% of UCTD patients commonly present a single autoantibody specificity [19] . Recently we reported two UCTD patients positive for ANA and anti-dense fine speckled 70 (DFS70) antibodies in which a monospecific finding of anti-DFS70 antibodies helped us to exclude a misdiagnosis of CTD [34] . These autoantibodies were traditionally detected by IIF assay on HEp-2 cells [35] . Recent studies have confirmed that monospecific anti-DFS70 autoantibodies are very uncommon in patients with autoimmune diseases. In many cases, the presence of these autoantibodies excludes the diagnosis of autoimmune diseases or the future development of autoimmunity in healthy subjects [3641] . Previous studies found that anti-DFS70 antibodies are more prevalent in individuals that do not have a well-defined CTD and in most cases can be detected in apparently healthy individuals [39, 42] . From these observations and from the preliminary data on the two case reports described, we enlarged the UCTD cohort studied, aiming to determine the prevalence of anti-DFS70 antibodies in a stable UCTD population to better define their potential role. Furthermore, we investigated the best laboratory strategy to identify these autoantibodies in the UCTD cohort, considering two different tests to detect anti-DFS70 antibodies.
Methods

Patients
Serum samples were obtained from 91 patients who were diagnosed as UCTD [87 females and 4 males; mean age 55 (15) years; mean disease duration 10 (3.3) years] who attended the Rheumatology Unit of San Giovanni di Dio Hospital, Florence (Italy), between June 2015 and September 2016. The inclusion criterion was diagnosis of UCTD with disease duration as assessed from the onset of the first symptom/sign 55years [14] . Dense fine speckled (DFS) pattern was determined using the IIF ANA test on HEp-2 cells and anti-DFS70 antibodies were tested by chemiluminescence immunoassay (CIA) and by DFS70 line immunoassay (LIA) [38, 40, 43 ]. All samples were tested for anti-dsDNA and anti-ENA by BioPlex 2200 multiplex flow immunoassay (MFI).
Serological analyses were performed blindly, and patient records and information remained anonymous. All patients gave their informed consent to this retrospective study according to the Declaration of Helsinki and to Italian legislation (Authorization of the Privacy Guarantor No. 9, 12 December 2013).
The institutional review board, the Health Director of San Giovanni di Dio Hospital in Florence, reviewed and approved this study and the use of clinical and laboratory data of common clinical practice, with respect to privacy law, for clinical and scientific studies and publications.
IIF assay on HEp-2 cells
The DFS samples were identified by IIF-ANA test on HEp-2 cells using the NOVA Lite DAPI ANA kit processed on the QUANTA Lyser Instrument (Inova Diagnostics, San Diego, CA, USA). The results were interpreted by manual microscope reading and using the NOVA View Instrument (Inova Diagnostics), an automated fluorescence microscope that provides IIF pattern recognition for confirmation. The NOVA View software also outputs light intensity units where each sample was interpreted as negative or positive based on a pre-set cut-off (light intensity unit 548 is positive). The samples were diluted with phosphate-buffered saline at 1: 80, according to the manufacturer's instructions. In brief: 30 ml of each diluted serum was incubated on one well with fixed HEp-2 cells. After incubation and rinsing off, the cells were incubated with FITC-IgG-conjugated antibody.
Anti-DFS70 antibodies detection by CIA Determination of anti-DFS70 antibodies was performed by CIA using QUANTA Flash DFS70 on the BIO-FLASH instrument (Inova Diagnostics). The antigen used in this test consisted of a recombinant DFS70 fragment expressed in Escherichia coli spanning amino acids 349435, coated onto paramagnetic beads [44] . In brief, the diluted sera were incubated with paramagnetic beads. After incubation and rinsing off, isoluminol-conjugated secondary antibodies were added. After additional washing the results were expressed in chemiluminescence units proportional to the amount of anti-DFS70 antibodies in the serum samples. The assay cut-off for reactivity was 20 chemiluminescence units.
Anti-DFS70 antibodies determined by LIA
All the 91 samples were tested by the EUROLINE ANA Profile 3 lineblot (Euroimmun AG, Lü beck, Germany; Ro60, Ro52, La, RNP, Sm, Scl70, CENP-B, PM-Scl, Jo-1, PCNA, dsDNA, nucleosomes, histones, ribosomal P-proteins, AMA M2, DFS70) using a full-length DFS70 antigen [45] . Sera were incubated in accordance with the manufacturer's standard protocol (30 min in serum, 30 min in antihuman immunoglobulin G/alkaline phosphatase and 10 min in 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium substrate). Reaction intensities expressed in greyscale units were automatically evaluated using commercially available EUROLineScan software (Euroimmun AG) and line intensity readings of >11 arbitrary units were considered specific.
Anti-dsDNA and anti-ENA analysed with BioPlex2200 ANA screen (MFI)
The BioPlex 2200 (Bio-Rad, Hercules, CA, USA) system is an automated analyser that uses multiplex bead technology (Luminex, Austin, TX, USA) to simultaneously detect antibodies to several antigens in a single tube.
The BioPlex 2200 ANA Screen kit is intended for the qualitative screening of ANAs, the quantitative detection of antibodies to dsDNA and the semi-quantitative detection of 10 separate antibodies (chromatin, ribosomal P, SS-A, SS-B, Sm, SmRNP, RNP, Scl-70, Jo-1 and centromere B) in human serum and/or EDTA or heparinized plasma. Magnetic particles (8 mm diameter, carboxyl surface) are dyed with two fluorophores (classification dyes, CL1 and CL2) which emit at distinct wavelengths and adsorb significantly at 635 nm. The reporter fluorophore, B-phycoerythrin (PE) was chosen for its high molar extinction coefficient, quantum yield, resistance to photobleaching, lack of self-quenching and stability. The detector simultaneously measures light at four wavelengths; the two classification dyes, the reporter dye and the scatter of incident light. Following removal of excess conjugate, the magnetic beads are passed through the detector. Analyte concentration is proportional to the fluorescence intensity. Results are expressed in IU/ml for anti-dsDNA and Antibody Index for ANA antibodies and the results' interpretation established by the manufacturer are 59 IU/ ml (indeterminate) and 510 IU/ml (positive) for dsDNA and 51.0 Antibody Index (positive) for ANA antibodies.
Statistical analysis
The data were processed and analysed using the statistical program MedCalc for Windows version 15.2 (MedCalc Software, Ostend, Belgium). Data are presented as mean (S.E.M.). Significance of differences was analysed by Student's t-test. For all statistical tests, P < 0.05 was considered significant.
Results
Twelve (13.3%) out of 91 subjects were positive for anti-DFS70 antibodies by CIA and LIA (Table 1 ). There were no significant differences between anti-ENA and anti-DNA antibody frequencies between patients with and without anti-DFS70 (P = 0.54 and P = 0.27, respectively). Considering the IIF-ANA testing, eight out of the 12 patients (75%) with anti-DFS70 autoantibodies showed a DFS pattern, and two of which had a second ANA pattern added. Moreover, two patients had a different pattern from the DFS pattern, and one was negative (Table 1) . There was no difference on ANA titre between patients with and without anti-DFS70 antibodies (P = 0.4). The clinical characteristics of UCTD patients with and without anti-DFS70 autoantibodies were analysed by retrospective chart review and are summarized in Table 2 . There were no statistical differences in the clinical characteristics of the two groups of patients. The mean age of patients with anti-DFS70 was significantly lower than subjects without anti-DFS70 [47 (13) vs 56 (16), P = 0.05]. There were no significant differences in the months of UCTD duration between patients with and without anti-DFS70 [9 (2) vs 10.4 (3.4), P = 0.13].
Discussion
In recent years, better knowledge about the UCTD condition as a distinct clinical entity has underlined the importance of identifying patients at high risk of developing a defined CTD. Up to 50% of CTDs do not have a clearly defined profile at disease onset [46] and are referred to as UCTD. Three years after diagnosis 3350% of UCTD However, since other patients do not develop specific clinical features or disease specific antibodies, reliable markers that may predict the evolution of UCTD to a defined form of CTD are important. The recently revised CTD classification and diagnostic criteria partially solved this critical point though there are still only a few biomarkers that predict UCTD evolution into defined CTD [14, 17] . Considering the therapeutic and prognostic impact of the disease, there is a great need for new serological markers that may help the clinician to differentiate stable and unstable UCTD. Relative to the serological profile, global ANA prevalence in UCTD is high, ranging from 58 to 100%. The IIF-ANA pattern can be considered an indicator of both high risk (i.e. homogeneous) and low risk (i.e. DFS), depending on the specific pattern considered [39, 40, 48] . Regarding the DFS IIF-ANA pattern, it can be difficult sometimes to accurately recognize it, resulting in misinterpretation. This is especially relevant when discriminating between DFS and mixed homogeneous and speckled or quasi-homogeneous patterns [40, 49, 50] . Additionally, the IIF-ANA test is not a reliable method to identify anti-DFS70 autoantibodies, because of its inconsistency [45] . The DFS pattern may be associated with the presence of anti-DFS70 antibodies but specific ANAs, including antidsDNA and anti-ENA, might lead to similar pattern recognition [51, 52] . In light of this, samples with DFS staining pattern identified by IIF should be tested for anti-DFS70 antibodies by a specific assay in order to avoid the misinterpretation of the ANA. Therefore the specific assays (CIA and LIA) are considered nowadays a better tool to identify the anti-DFS70 autoantibodies [45] . Our data (k = 0.95) reinforced the excellent agreement between the two methods reported in literature and for this reason they can both be used interchangeably in the detection of the anti-DFS70 antibodies [38, 51, 5356] . Additionally, consistent with the previous findings, we confirmed the remarkable prevalence in the UCTD individuals and the highest prevalence of anti-DFS70 antibodies in young females [54] . However, this finding has not been found in a recent paper on a large cohort of SLE patients [57] . The existing literature showed a high but heterogeneous prevalence of anti-DFS70 antibodies in UCTD patients ranging from 8.3 to 40% [36, 55] , depending on the method used. We felt these data were worthy of further consideration and insights, and so we focused on a longstanding UCTD population to better define the role of antibodies as well as the best laboratory strategy, considering the currently available methods. Because our study confirmed the marker's high frequency in the UCTD population studied (13.3%) and because it is uncommon in CTD patients, it follows that nowadays anti-DFS70 antibodies could represent a serological marker for UCTD and a reliable tool for excluding the evolution of UCTD to CTD. Taking into consideration the high prevalence of this condition in the rheumatology field and that a great percentage of UCTD patients will remain undifferentiated during follow-up, the cost-saving impact in developing predictive factors of evolution is increasingly clear. Since the 66.7% of the anti-DFS70 positive patients (8/12) were negative for anti-ENA and/ or anti-dsDNA, the ANA testing could be interpreted as an ANA negative result in such situations, without any overestimation of the CTD evaluation diagnosis due to the ANA report. Consequently, detection of anti-DFS70 antibodies should be included in ANA testing algorithms to aid in interpreting ANA positivity in UCTD patients. The DFS pattern can be detected in ANA testing and it may act as an exclusion marker, especially when monospecific anti-DFS70 specificity is found. In fact, over the past decade monospecific anti-DFS70 antibodies have proved to be a crucial element in a reverse diagnostic flowchart [51] and therefore, similarly, in the UCTD population they could stratify patients at low risk for the CTD condition.
The main limitation of the study was that we could not include a control group of a retrospective UCTD cohort developing a CTD in their next follow-up. However, it will be interesting to closely monitor the patients studied in the current paper for any changes in the clinical and serological phenotype of CTD over the years. Larger and prospective studies are needed to support these preliminary data and to better define the predictive role of anti-DFS70 antibodies in UCTD patients. Funding: No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript.
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